Promising 'Youth Molecule' NAD+ Could Enhance Quality of Life in Aging Populations

Researchers from the University of Oslo, Akershus University Hospital, and international partners have published a comprehensive expert opinion in Nature Aging, highlighting the potential of NAD+ (nicotinamide adenine dinucleotide) as a key factor in promoting healthier aging. This collaborative effort involved over 25 scientists, including clinicians and experts in aging biology and metabolism, bringing attention to NAD+'s critical role in cellular functions.

NAD+ is often referred to as a cell's 'fuel regulator' because it is essential for energy production, DNA repair, and maintaining cellular health. However, NAD+ levels naturally decline with age, which has been associated with various age-related issues such as memory decline, muscle weakness, and increased susceptibility to diseases like Alzheimer’s and Parkinson’s.

The recent review underscores that targeting NAD+ metabolism could be a promising strategy to delay aging processes and prevent age-related diseases. Dr. Jianying Zhang, a lead author, emphasized the importance of understanding optimal dosing, long-term safety, and individual responses to NAD+ enhancement interventions.

Various clinical trials have explored methods to boost NAD+ levels, primarily through supplements like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). Early data from these studies have shown promising results, including improvements in cognition, mobility, and metabolic health. Nevertheless, the authors stress that larger, more comprehensive studies are necessary to confirm these benefits and determine the most effective and safe approaches.

This publication arrives at a time of heightened scientific and public interest, as multiple ongoing clinical trials worldwide investigate NAD+ precursors. These supplements have gained popularity globally, fueling debates about their effectiveness and the translatability of animal research findings to human health.

Dr. Evandro Fei Fang-Stavem, senior author of the paper, noted the importance of consolidating current evidence and providing a clear scientific framework for future research and clinical applications. Meanwhile, Prof. Torbjørn Omland pointed out that this review helps bridge the gap between basic scientific understanding and clinical practice, especially for conditions like neurological and cardiovascular diseases.

The authors conclude that while NAD+ biology presents exciting therapeutic possibilities, large-scale collaboration and rigorous testing are crucial for transforming this promising science into safe and effective age-related treatments.